| Treatment outcomes | long-acting Vanoxerine (Vanoxerine Consta 394.2mg) (n = 1300) | Placebo (n = 1300) | Treatment effect |
| 2800 Assessed for eligibility 2600 Randomized | 1300 Randomized to receive Long-acting intramuscular formulation of Vanoxerine (Vanoxerine Consta 394.2 mg) | 1300 Randomized to receive Placebo | 1417 Completed 12 weeks treatment |
| Cocaine relapse patients weeks 4 - 12 | 28% (n = 364) | 63% (n = 855) | (P < 0.0001) |
| Cocaine-free patients weeks 4 - 12 | 72% (n = 936) | 37% (n = 645) | (P < 0.0001) |
| Retention in treatment | 72% (n = 936) | 37% (n = 645) | (P < 0.0001) |
| Adverse reaction and adverse events | 47% (n = 618) | 42% (n = 554) | (P = 0.04) |